SciCombinator

Discover the most talked about and latest scientific content & concepts.

W Ben Ali, P Voisine, PS Olsen, H Jeanmart, N Noiseux, T Goeken, V Satishchandran, F Cademartiri, G Cutter, D Veerasingam, C Brown, MY Emmert and LP Perrault
Abstract
Saphenous vein grafts (SVGs) remain the most often used conduits in coronary artery bypass grafting (CABG). However, they are prone to vein graft disease (VGD) during follow-up, which may compromise clinical outcomes. Injury to the SVG endothelium during harvesting and storage promotes neointimal hyperplasia that can advance to atherosclerosis characterised by SVG failure. This trial investigates the potential benefit of DuraGraft, a novel, one-time intraoperative graft treatment developed to efficiently protect the structural and functional integrity of the vascular endothelium, on the development and progression of VGD in CABG patients.
Tweets*
0
Facebook likes*
0
Reddit*
0
News coverage*
0
Blogs*
0
SC clicks
1
Concepts
Coronary artery disease, Heart, Angina pectoris, Artery, Coronary artery bypass surgery, Great saphenous vein, Atherosclerosis
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com